Concepedia

Extended interval dosing with ocrelizumab in multiple sclerosis

Frederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard, Jonas M. Berg, Jonna Skov Madsen, Dorte Aalund Olsen, Inga Urbonavičiūtė, Zsolt Illés, Morten Stilund, Jeppe Romme Christensen,

Multiple Sclerosis Journal · 2024 · 18 citations · 16 references

DOIFull text

Open access

Abstract

Extending one treatment interval of ocrelizumab on average 9 weeks and up to 78 weeks did not result in clinical, radiological, or biomarker evidence of worsening compared with SID.

References

16

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text

Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis

Petra Roll, Arumugam Palanichamy, Christian Kneitz et al. · Arthritis & Rheumatism · 2006 · 316 citations

Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults

Claus Vinter Bødker Hviid, Cindy Soendersoe Knudsen, Tina Parkner · Scandinavian Journal of Clinical and Laboratory Investigation · 2020 · 131 citations

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer et al. · Neurology Neuroimmunology & Neuroinflammation · 2021 · 106 citations · Full text